Table 1.
Longevity of the Nabs and SARS-CoV-2 spike binding antibody responsea
| Diabetes | Days from symptom | n | Neutralizing Antibody titers | SARS-Cov2 RBD IgG | SARS-Cov2 RBD IgM | SARS-Cov2 S1 + S2 IgG | |
|---|---|---|---|---|---|---|---|
| Sample at admission | No | 10.5 (7-16) | 110 | 539 (10-3358) | 4.89 (0.16-29) | 4.79 (1.68-12.15) | 29.35 (2.2-95.55) |
| Yes | 11 (6-17.75) | 40 | 1550 (20-7998) | 10.4 (0.3-87.4) | 4.96 (1.63-9.8) | 47.54 (4.58-96.39) | |
| P = .247 | P = .294 | P = .769 | P = .478 | ||||
| First visit | No | 42 (37-51) | 63 | 3593 (1753-6419) | 1261 (739-4097) | 4.89 (2.44-8.97) | 7739 (4153-16 673) |
| Yes | 43 (31-53.2) | 12 | 3771 (2328-6042) | 1756 (634-9739) | 3.05 (1.55-8.13) | 8285 (4827-20 439) | |
| P = .977 | P = .654 | P = .312 | P = .718 | ||||
| Second visit | No | 99 (95-109) | 61 | 819 (442-2022) | 2328 (850-4988) | 1.74 (0.74-5.12) | 5757 (2422-11 163) |
| Yes | 102 (93-114) | 11 | 968 (817-1980) | 3647 (980-5262) | 1.37 (0.88-4.39) | 9440 (3119-17 847 | |
| P = .536 | P = .973 | P = .244 | P = .352 | ||||
| Third visit | No | 209 (203-219) | 35 | 660 (387-1706) | 5565 (2423-9711) | — | 5176 (1932-8782) |
| Yes | 209 (192-215) | 5 | 588 (270-710) | 5292 (1956-10 019) | — | 7809 (1905-9282) | |
| P = .449 | P = .905 | P = .837 |
Neutralizing antibody titers are expressed as the reverse of the serum dilution giving a ID50.
aMedian titer was calculated on all available samples.